Page 2 - Optune Gio News Today

NovoCure Limited (NASDAQ:NVCR – Get Free Report) has earned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among analysts […]

Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have been given an average recommendation of “Moderate Buy” by the nine research firms that are currently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average […]

NovoCure (NASDAQ:NVCR – Free Report) had its target price trimmed by Wells Fargo & Company from $49.00 to $42.00 in a report issued on Wednesday morning, Benzinga reports. The brokerage currently has an overweight rating on the medical equipment provider’s stock. Other analysts have also recently issued research reports about the company. HC Wainwright upped […]

NovoCure (NASDAQ: NVCR) has recently received a number of price target changes and ratings updates: 4/3/2024 – NovoCure had its price target lowered by analysts at Wells Fargo & Company from $49.00 to $42.00. They now have an “overweight” rating on the stock. 3/27/2024 – NovoCure had its “neutral” rating reaffirmed by analysts at Wedbush. […]

NovoCure (NASDAQ:NVCR – Get Free Report) had its target price lowered by investment analysts at Wells Fargo & Company from $49.00 to $42.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price objective indicates a potential upside […]

NovoCure (NASDAQ:NVCR – Get Free Report) and Minerva Surgical (NASDAQ:UTRS – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends. Institutional and Insider Ownership 84.6% of NovoCure shares […]

Wedbush reissued their neutral rating on shares of NovoCure (NASDAQ:NVCR – Free Report) in a report published on Wednesday, RTT News reports. The firm currently has a $21.00 price target on the medical equipment provider’s stock. Wedbush also issued estimates for NovoCure’s Q4 2025 earnings at ($0.36) EPS, FY2026 earnings at ($1.45) EPS and FY2027 […]

NovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Call Transcript February 22, 2024 NovoCure Limited isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. Welcome to the NovoCure Q4 2023 Earnings Conference Call. At this […]

Operator: Good day and thank you for standing by. Welcome to the NovoCure Q4 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.